

**AMENDMENTS TO THE CLAIMS  
PURSUANT TO REVISED 37 CFR § 1.121**

**Listing Of Claims:**

- 1 - 10. (Cancelled)
11. (Withdrawn) A method for the detection of a demyelinating disease comprising:
- a) providing:
    - i) a fluid sample from a human suspected of having a demyelinating disease;
  - b) reacting said fluid sample with human ferritin binding protein; and
  - c) detecting the binding of antibodies within said fluid sample to said ferritin binding protein.
12. (Withdrawn) The method of Claim 11, wherein said fluid sample is selected from the group consisting of whole blood, blood serum, blood plasma, cerebral spinal fluid, lymph, and urine.
13. (Withdrawn) The method of Claim 11, wherein said ferritin binding protein is immobilized prior to said reacting of step (b).
14. (Withdrawn) The method of Claim 13, wherein said ferritin binding protein is immobilized on a substrate selected from the group consisting of glass, agarose, and plastic.
15. (Withdrawn) The method of Claim 11, wherein said substrate comprising ferritin binding protein comprises ferritin binding protein operably linked with a resin.
16. (Withdrawn) A isolated ferritin binding protein having an observed molecular weight of approximately 55 kDa.

17 - 26. (Cancelled)

27. (Previously Presented) A method for the detection of multiple sclerosis comprising:

- a) providing:
  - i) a brain tissue sample, having a periplaque region, from a human suspected of having a demyelinating disease and
  - ii) transferrin;
- b) reacting, in vitro, said brain tissue sample with transferrin; and
- c) evaluating said periplaque region for binding with transferrin wherein a finding of transferrin binding, in said periplaque region, confirms the detection of multiple sclerosis in said brain tissue sample.